Qingdao Baheal Medical Past Earnings Performance
Past criteria checks 6/6
Qingdao Baheal Medical has been growing earnings at an average annual rate of 21.5%, while the Healthcare industry saw earnings growing at 4.2% annually. Revenues have been growing at an average rate of 11.1% per year. Qingdao Baheal Medical's return on equity is 24.2%, and it has net margins of 8.7%.
Key information
21.5%
Earnings growth rate
18.9%
EPS growth rate
| Healthcare Industry Growth | 7.0% |
| Revenue growth rate | 11.1% |
| Return on equity | 24.2% |
| Net Margin | 8.7% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Qingdao Baheal Medical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 7,564 | 656 | 1,300 | 11 |
| 30 Sep 23 | 7,486 | 651 | 1,323 | 13 |
| 30 Jun 23 | 7,414 | 588 | 1,335 | 11 |
| 31 Mar 23 | 7,336 | 537 | 1,312 | 6 |
| 31 Dec 22 | 7,510 | 502 | 1,332 | 3 |
| 30 Sep 22 | 7,336 | 458 | 1,238 | 2 |
| 30 Jun 22 | 7,436 | 451 | 1,255 | 1 |
| 31 Mar 22 | 7,286 | 423 | 1,224 | 0 |
| 01 Jan 22 | 7,052 | 422 | 1,128 | 0 |
| 30 Sep 21 | 7,038 | 421 | 1,192 | 0 |
| 30 Jun 21 | 6,797 | 349 | 1,137 | 0 |
| 31 Mar 21 | 6,291 | 303 | 1,047 | 0 |
| 31 Dec 20 | 5,879 | 273 | 1,023 | 0 |
| 31 Dec 19 | 4,849 | 210 | 990 | 0 |
| 31 Dec 18 | 3,652 | 258 | 829 | 0 |
| 31 Dec 17 | 3,096 | 222 | 756 | 0 |
| 31 Dec 16 | 3,034 | 184 | 773 | 0 |
| 31 Dec 15 | 2,392 | 73 | 707 | 0 |
Quality Earnings: 301015 has high quality earnings.
Growing Profit Margin: 301015's current net profit margins (8.7%) are higher than last year (6.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 301015's earnings have grown significantly by 21.5% per year over the past 5 years.
Accelerating Growth: 301015's earnings growth over the past year (30.7%) exceeds its 5-year average (21.5% per year).
Earnings vs Industry: 301015 earnings growth over the past year (30.7%) exceeded the Healthcare industry -1%.
Return on Equity
High ROE: 301015's Return on Equity (24.2%) is considered high.